Pediatric antihypertensive trial failures - Analysis of end points and dose range

被引:75
作者
Benjamin, Daniel K., Jr. [1 ,3 ,4 ,5 ,6 ]
Smith, P. Brian [1 ,3 ,4 ,5 ,6 ]
Jadhav, Pravin [2 ]
Gobburu, Jogarao V. [2 ]
Murphy, M. Dianne [1 ]
Hasselblad, Vic [3 ,4 ,5 ,6 ]
Baker-Smith, Carissa [3 ,4 ,5 ,6 ]
Califf, Robert M. [7 ]
Li, Jennifer S. [1 ,3 ,4 ,5 ,6 ]
机构
[1] US FDA, Off Pediat Therapeut, Off Commissioner & Pharmacometr, Rockville, MD 20857 USA
[2] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
[3] Duke Univ, Dept Pediat, Durham, NC 27706 USA
[4] Duke Univ, Dept Biostat, Durham, NC 27706 USA
[5] Duke Univ, Dept Med, Durham, NC 27706 USA
[6] Duke Univ, Duke Clin Res Inst, Durham, NC 27706 USA
[7] Duke Univ, Duke Translat Med Inst, Durham, NC 27706 USA
关键词
pediatrics; antihypertensive agents; dose-response relationship; clinical trials; randomized; pediatric epidemiology;
D O I
10.1161/HYPERTENSIONAHA.107.108886
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Historically, drugs prescribed for children have not been studied in pediatric populations. Since 1997, however, a 6-month extension of marketing rights is granted if manufacturers conduct Food and Drug Administration-defined pediatric trials. In nearly half of the drugs studied, there were unexpected results in dosing, safety, or efficacy compared with adult studies, including failure of half of the antihypertensive dose-response trials, which are pivotal for deriving dosing recommendations. We sought to define design elements that might have contributed to these trial failures by combining patient-level data from 6 dose-ranging antihypertensive efficacy trials completed for pediatric exclusivity and submitted to the Food and Drug Administration from 1998 to 2005. We evaluated dosing, primary end point, and other components to assess underlying reasons for failure to show efficacy in children. Of 6 trials examined, 3 showed a dose response; 3 did not. Eligibility criteria were similar across studies, as were subject demographics. Successful studies showed large differences in doses, with little or no overlap between low, medium, and high doses; failed trials used narrow dose ranges with considerable overlap. Successful trials also provided pediatric formulations and used reduction in diastolic, not systolic, blood pressure as the primary end point. Careful attention to pediatric pharmacology and selection of primary end points can improve trial performance. We found poor dose selection, lack of acknowledgement of differences between adult and pediatric populations, and lack of pediatric formulations to be associated with failures. More importantly, our ability to combine data across trials allowed us to evaluate and potentially improve trial design.
引用
收藏
页码:834 / 840
页数:7
相关论文
共 19 条
[1]   Peer-reviewed publication of clinical trials completed for pediatric exclusivity [J].
Benjamin, Daniel K., Jr. ;
Smith, Philip Brian ;
Murphy, M. Dianne ;
Roberts, Rosemary ;
Mathis, Lisa ;
Avant, Debbie ;
Califf, Robert M. ;
Li, Jennifer S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (10) :1266-1273
[2]   Pharmacokinetics of quinapril in children: Assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment [J].
Blumer, JL ;
Daniels, SR ;
Dreyer, WJ ;
Batisky, D ;
Walson, PD ;
Roman, D ;
Ouellet, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (02) :128-132
[3]  
*CDCP, SAS PROGR CDC GROWTH
[4]   A randomized, placebo-controlled trial of amlodipine in children with hypertension [J].
Flynn, JT ;
Newburger, JW ;
Daniels, SR ;
Sanders, SP ;
Portman, RJ ;
Hogg, RJ ;
Saul, JP .
JOURNAL OF PEDIATRICS, 2004, 145 (03) :353-359
[5]   Is the extrapolated adult dose of Fosinopril safe and effective in treating hypertensive children? [J].
Li, JS ;
Berezny, K ;
Kilaru, R ;
Hazan, L ;
Portman, R ;
Hogg, R ;
Jenkins, RD ;
Kanani, P ;
Cottrill, CM ;
Mattoo, TK ;
Zharkova, L ;
Kozlova, L ;
Weisman, I ;
Deitchman, D ;
Califf, RM .
HYPERTENSION, 2004, 44 (03) :289-293
[6]  
PARK MK, 1987, PEDIATRICS, V79, P907
[7]   Pediatric drug labeling - Improving the safety and efficacy of pediatric therapies [J].
Roberts, R ;
Rodriguez, W ;
Murphy, D ;
Crescenzi, T .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :905-911
[8]  
RODRIGUEZ W, IN PRESS PEDIATRICS
[9]   The pharmacokinetics of irbesartan in hypertensive children and adolescents [J].
Sakarcan, A ;
Tenney, F ;
Wilson, JT ;
Stewart, JJ ;
Adcock, KG ;
Wells, TG ;
Vachharajani, NN ;
Hadjilambris, OW ;
Slugg, P ;
Ford, NF ;
Marino, MR .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (07) :742-749
[10]   A double-blind, dose-response study of losartan in hypertensive children [J].
Shahinfar, S ;
Cano, F ;
Soffer, BA ;
Ahmed, T ;
Santoro, EP ;
Zhang, ZX ;
Gleim, G ;
Miller, K ;
Vogt, B ;
Blumer, J ;
Briazgounov, I .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (02) :183-190